|
Antimicrobial agent
|
Total (n = 139)
|
Hospital-onset (n = 60)
|
Community-onset
|
CTX-M type
| | |
|---|
| | | |
Total (n = 79)
|
Healthcare-associated (n = 46)
|
Community-associated (n = 33)
|
CTX-M-14 (n = 69)
|
CTX-M-15 (n = 53)
|
CTX M-14 + M-15 (n = 17)
|
|---|
|
Amikacin
|
14 (10.1)
|
7 (11.7)
|
7 (8.9)
|
3 (6.5)
|
4 (12.1)
|
4 (5.8)
|
7 (13.2)
|
3 (17.6)
|
|
Gentamicin
|
92 (65.5)
|
45 (73.8) a
|
47 (59.5)
|
28 (60.9)
|
19 (57.6)
|
37 (53.6)
|
40 (75.5)b
|
15 (88.2)b
|
|
Tobramycin
|
94 (67.6)
|
46 (76.7)
|
48 (60.8)
|
29 (63.0)
|
19 (57.6)
|
36 (52.2)
|
43 (81.1)b
|
15 (88.2) b
|
|
Aztreonam
|
130 (93.5)
|
60 (100)
|
70 (88.6)
|
43 (93.5)
|
27 (81.8)
|
62 (89.9)
|
51 (96.2)
|
17 (100)
|
|
Cefepime
|
132 (95.0)
|
58 (96.7)
|
74 (93.7)
|
44 (95.7)
|
30 (90.9)
|
65 (94.2)
|
51 (96.2)
|
16 (94.1)
|
|
Ceftazidime
|
77 (55.4)
|
38 (63.9)
|
39 (49.4)
|
24 (52.2)
|
15 (45.5)
|
20 (29.0)
|
43 (81.1)b
|
14 (82.4) b
|
|
Cefotaxime
|
139 (100)
|
60 (100)
|
78 (100)
|
46 (100)
|
32 (100)
|
69 (100)
|
52 (100)
|
17 (100)
|
|
Ciprofloxacin
|
105 (75.5)
|
52 (86.7) a
|
53 (67.1)
|
34 (73.9)
|
19 (57.6)
|
47 (68.1)
|
42 (79.2)
|
16 (94.1)b
|
|
Piperacillin-tazobactam
|
33 (23.7)
|
20 (33.3) a
|
13 (16.5)
|
7 (15.2)
|
6 (18.2)
|
11 (15.9)
|
10 (18.9)
|
12 (70.6) b,c
|
|
Trimethoprim-sulfamethoxazole
|
89 (64.0)
|
38 (63.3)
|
51 (64.6)
|
29 (63.0)
|
22 (66.7)
|
52 (75.3)
|
31 (58.5) b
|
6 (35.3) b
|
|
Multidrug resistance
|
120 (86.3)
|
53 (88.4)
|
67 (84.8)
|
39 (84.8)
|
28 (84.8)
|
55 (79.7)
|
48 (90.6)
|
17 (100)b
|
|
Resistance scored ≥ 3
|
71 (51.1)
|
39 (65.0) a
|
32 (40.5)
|
19 (41.3)
|
13 (39.4)
|
26 (37.7)
|
31 (58.5) b
|
14 (82.4) b
|
-
a For comparison with CO isolates, P < 0.05.
-
b For comparison with CTX-M-14 producing isolates, P < 0.05.
-
c For comparison with CTX-M-15 producing isolates, P < 0.001.
-
d Number of antimicrobial classes, apart from penicillin and cephalosporin, to which E. coli isolates are non-susceptible.
